{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma:\n\nDuration of Response (DOR)-Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.","groups":[{"description":"CAR-T cells administered via intravenous infusion as a total dose","id":"OG000","title":"Phase 2: P-BCMA-101 CAR-T Cells"}],"populationDescription":"Independent Review Committee (IRC) was not formed to assess DOR as the Phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.","reportingStatus":"POSTED","timeFrame":"Baseline through 24 months","title":"Phase 2: Assess the Efficacy of P-BCMA-101 (DOR)","type":"PRIMARY"}